# ExpressCells

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/expresscells

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.xpresscells.com
- Total disclosed funding: $1M
- Latest round: Series A (Apr 8, 2021)
- Investors on record: 8

## About

Based in Philadelphia, US, and founded in 2018, ExpressCells operates as a biotechnology company that creates knock-in cell lines for biological research and uses CRISPR plus a proprietary genetic vector system to create custom cells for research. In April 2021, ExpressCells raised USD 590,500 in series A2 funding from MIT Alumni Angels of Northern California, Tech Coast Angels, and Berkeley Angel Network, with participation from Ben Franklin Technology Partners, etc.

ExpressCells assists in making precise cuts into a cell's genome and then uses a patent-pending plasmid system to insert new genes into the cell to create a genetically altered cell line, allowing researchers to visualize proteins and organelles inside the cell.

The company plans to use the funding to support operations expansion and increased promotion.

## Funding rounds

- Series A, Apr 8, 2021, $0.6M — Ben Franklin Technology Partners, Tech Coast Angels, Robin Hood Ventures, Central Texas Angel Network, Berkeley Angel Network, MIT Alumni Angels of Northern California, Rowan University
- Series A, Sep 27, 2019, $0.4M — Ben Franklin Technology Partners, Robin Hood Ventures, Central Texas Angel Network, Rowan University, Keiretsu Forum Mid-Atlantic

## Investors

- Ben Franklin Technology Partners (https://capitalatlas.ai/funds/ben-franklin-technology-partners) — Series A
- Robin Hood Ventures (https://capitalatlas.ai/funds/robin-hood-ventures) — Series A
- Central Texas Angel Network — Series A
- Rowan University — Series A
- Keiretsu Forum Mid-Atlantic — Series A
- Tech Coast Angels — Series A
- Berkeley Angel Network — Series A
- MIT Alumni Angels of Northern California — Series A